PDF
Fc-null anti-CTLA-4 antibody: a novel strategy to facilitate cancer immunotherapy by ridding the colitis-inducing mishap
Jingjing Chen1,2, Dexuan Wang2(
), Hu Zhang1()
PDF
Fc-null anti-CTLA-4 antibody: a novel strategy to facilitate cancer immunotherapy by ridding the colitis-inducing mishap
), Hu Zhang1()| 1 | BC Lo, I Kryczek, J Yu, et al. Microbiota-dependent activation of CD4(+) T cells induces CTLA-4 blockade-associated colitis via Fcγ receptors. Science. 2024;383(6678):62-70. doi: |
| 2 | F Martins, L Sofiya, GP Sykiotis, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563-580. doi: |
| 3 | AM Luoma, S Suo, HL Williams, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(3):655-671. doi: |
| 4 | Y Sato, CN Casson, A Matsuda, et al. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy. Cancer Immunol Immunother. 2022;71(10):2421-2431. doi: |
| 5 | W Ise, M Kohyama, KM Nutsch, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol. 2010;11(2):129-135. doi: |
/
| 〈 |
|
〉 |
AI Summary
